ONMEL (itraconazole) by Bel Air Pharmaceuticals is cytochrome p450 3a4 inhibitors [moa]. First approved in 2010.
Drug data last refreshed 1h ago · AI intelligence enriched 1mo ago
ONMEL is an oral tablet formulation of itraconazole, a triazole antifungal agent approved in 2010. It works by inhibiting cytochrome P450 3A4, disrupting ergosterol synthesis in fungal cell membranes. ONMEL treats various fungal infections in patients who require systemic antifungal therapy.
As LOE approaches in 2028, the brand team is likely contracting; roles will shift toward managing generic transition and protecting remaining market share against 15 direct competitors.
Cytochrome P450 3A4 Inhibitors
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Single-center, Randomized, Open-label, Parallel-design Clinical Study to Evaluate the Pharmacokinetic Effects of Itraconazole, Fluconazole or Efavirenz on a Single Dose of Clifutinib in Healthy Participants
In Vitro Susceptibility of Dermatophytes to Terbinafine and Itraconazole: MIC Distributions and Elevated-MIC Isolates in Faisalabad, Pakistan
Effect of a Known P-glycoprotein (P-gp) Inhibitor, Itraconazole, on the Pharmacokinetics (PK) of Engasertib
A Drug-drug Interaction Study to Assess the Effect of Phenytoin and Itraconazole on the Pharmacokinetics of Pelabresib in Healthy Participants
A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar Disorder
Worked on ONMEL at Bel Air Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in ~2 years — expect lifecycle management and generic defense hiring
With zero linked job openings and approaching LOE, ONMEL offers limited career growth or advancement potential. Roles on this product are contracting, making it a transitional assignment rather than a destination for ambitious professionals seeking development in a growth franchise.